Medical management of Parkinson's disease.
Clarke
C E
CE
Department of Neurology, City Hospital NHS Trust, Birmingham, UK. c.e.clarke@bham.ac.uk
D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009460:Neurologic Examination / Q000187:drug effects; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*
D018680:Cholinergic Antagonists; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists; D018696:Neuroprotective Agents; D007980:Levodopa; D000547:Amantadine